Edwards Lifesciences Misses Q2 EPS by 1c, Q3 Revenue Guidance Misses QA

  • Investing.com
Edwards Lifesciences Misses Q2 EPS by 1c, Q3 Revenue Guidance Misses QA

Edwards Lifesciences (NYSE: EW ) reported Q2 EPS of $0.63, $0.01 worse than the analyst estimate of $0.64. Revenue for the quarter came in at $1.37 billion versus the consensus estimate of $1.4 billion.

GUIDANCE:

Edwards Lifesciences sees Q3 2022 EPS of $0.58-$0.66, versus the consensus of $0.65. Edwards Lifesciences sees Q3 2022 revenue of $1.3-1.37 billion, versus the consensus of $1.44 billion.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100